You are here: 
text zoom : S | M | L
Printer Friendly Version


Discipline of Obstetrics and Gynaecology
School of Medicine

The University of Adelaide

 

Women's and Children's Hospital

King William Road

North Adealide SA 5006

AUSTRALIA

 

Email
Phone: +61 8 8161 7619
Facsimile: +61 8 8161 7652

MAGENTA: Magnesium sulphate at 30 to 34 weeks' gestational Age: Neuroprotection Trial.

ACTRN12611000491965

This trial is currently recruiting. The trial is open for other centres in Australia and New Zealand to join. Contact

Babies born very preterm have a greater risk of significant morbidities including neurologic impairments such as cerebral palsy. The risk of morbidity increases with decreasing gestational age at birth. The Cochrane review evaluating the effect of magnesium sulphate on neuroprotection of the fetus shows that magnesium sulphate given to women at risk of imminent preterm birth reduces the risk of cerebral palsy. It remains unclear at which gestational age treatment will be beneficial.

The National Clinical Practice Guidelines on Antenatal Magnesium Sulphate prior to preterm birth of the fetus, infant and child recommends further randomised trials at 30 weeks' gestation or more. This had led to the MAGENTA Study.

Funding: NHMRC Project Grant 2012-2016
Chief Investigators:           Professor Caroline Crowther, Ms Philippa Middleton, A/Professor Dominic Wilkinson, A/Professor Ross Haslam
Clinical Trial Coordinator: Ms Pat Ashwood, Ms Daniela Gagliardi, Ms Michaela Jarrett
Email: magenta@adelaide.edu.au
Address: Contact Us
Phone: 61 8 8161 7767
Fax: 61 8 8161 7652
Collaborating Centres:  

Australia

 

 

SA - Women's & Children's Hospital
Flinders Medical Centre
NSW - Royal Hospital for Women (Sydney)
Royal North Shore Hospital
St George Hospital (Sydney)
QLD - Mater Mother's Hospital
Ipswich Hospital
Nambour Hospital
Redcliffe Hospital
The Townsville Hospital
VIC - The Women's Hospital (Melbourne)
Mercy Hospital for Women
Sunshine Hospital
TAS - Royal Hobart Hospital
Launceston General Hospital

New Zealand

Auckland City Hospital
Christchurch Hospital
Middlemore Hospital
Dunedin Hospital

References

  • Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child: National clinical practice guidelines. 2010 Adelaide, The University of Adelaide (Guidelines)
  • Crowther CA, Middleton PF, Wilkinson D, Ashwood P, Haslam R, MAGENTA Study Group. Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. BMC Preg Childbirth. 2013;13. (Protocol)
  • Nguyen TMN, Crowther CA,Wilkinson D, Bain E. Magnesium sulphate for women at term for neuroprotection of the fetus. Cochrane Database of Systematic Reviews 2013, Issue 2. (Review)
  • Doyle L, Crowther C, Middleton P, Voysey M, Marret S, Rouse D. Antenatal magnesium sulphate to prevent cerebral palsy in very preterm infants. BJOG 2011;118(7):891-892. (Letter)
  • Nguyen TN, Crowther CA, Wilkinson D. Magnesium sulphate for women at term for neuroprotection of the fetus (Protocol). Cochrane Database Syst Rev. 2011, Issue 10.
  • Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2010, Issue 1.
  • Doyle L, Crowther C. et al. Antenatal magnesium sulphate and neuroprotection for very preterm infants - The Updated Cochrane review. J Paediatrics and Child Health 2009;45(suppl 1): A47
  • Crowther CA, Doyle LW. et al. Outcomes at 2 years of age after repeat doses of antenatal corticosteroids. New Engl J Med 2007;357(12): 1179-1189. (Article)
  • Crowther, CA, JE. Hiller, et al. Effect of magnesium sulfate given for neuroprotection before preterm birth - A randomized controlled trial. JAMA 2003;290(20): 2669-2676. (Article)
  • Crowther CA, Hiller JE. et al. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane database Syst Rev 2002, Issue 4.